Drugs / ART0380
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04657068 | Jan 2021 → Dec 2026 expected | acinar cell carcinoma, colorectal cancer, endometrial cancer, fallopian tube cancer +4 | Artios Pharma Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05798611 | Sep 2023 → Nov 2024 | endometrial cancer, metastatic malignant neoplasm | Artios Pharma Ltd | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART0380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04657068 ↗ |
| Action | Inhibit | “potent and selective inhibitor of Ataxia telangiectasia and Rad3-related (ATR)” NCT04657068 ↗ |
| Route | Oral | “Participants will receive ART0380 by mouth” NCT04657068 ↗ |
| Target | ATR | “inhibitor of Ataxia telangiectasia and Rad3-related (ATR)” NCT04657068 ↗ |